Multimodal Investigation of Intracranial Clot Environment

Brain Ischemia Clinical Trial

— MISO  

Official title:

Multimodal Investigation of Intracranial Clot Environment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04421326
• Other study ID #: RECHMPL18_0236
• Status: Recruiting
• Start date: March 14, 2021
• Est. completion date: October 2025

Study information

• Verified date: May 2024
• Source: University Hospital, Montpellier
• Contact: Cyril DARGAZANLI, MD MSc
• Phone: 467337532
• Email: c-dargazanli[@]chu-montpellier.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Analysis of peri clot blood collected at the acute phase of stroke in order to understand physiopathological mechanisms involved in the cerebrovascular damage

Description:

It has been shown that immune cells accumulate around the clot at the acute phase of stroke. Leukocytes and their specific chemokines and cytokines regulation may impact cerebrovascular integrity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: October 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion criteria:

1. Over 18 years of age,

2. Non-dependent for activities of daily living prior to the onset of the MI (Modified Rankin Score >2)

3. Having an occlusion of a large arterial trunk proven by imaging (angio-MRI or angio-scanner).

Exclusion criteria:

1. Patients initially admitted but for whom endovascular treatment will not finally be performed (re-infusion, catheterization failure...) will be excluded from the study.

2. Major patients under guardianship or curatorship or patients deprived of liberty

Related Conditions & MeSH terms

• Acute Ichemic Stroke
• Brain Ischemia
• Ischemia

Intervention

Other:
• Analysis of the clot
Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy

Locations

Country	Name	City	State
France	University Hospital of Montpellier	Montpellier

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Montpellier	Genomic Institute of Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metalloproteinase 9 quantification		60 months
Primary	Metalloproteinase 2 quantification		60 months
Secondary	Cytokines levels	Proteomic analysis of cytokines IL-1ß, TNF-a, IL-6	60 months